| Name | Title | Contact Details |
|---|
SI-BONE, Inc. (San Jose, California) is the leading sacroiliac joint medical device company dedicated to the development of tools and products for patients with low back issues related to certain SI joint disorders. The company has developed, and is manufacturing and marketing, minimally invasive products for patients with certain SI joint disorders. SI-BONE has an experienced management team with extensive experience in orthopedic and spine medical devices.
LXN Corporation is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
One of every nine Americans is a member of an Anthem, Inc. affiliated health plan. For us, that`s a tremendous privilege and responsibility. Our focus every day is on improving the lives of the people we serve and the health of our communities. The foundation of our work can be summarized by: Delivering consistent service and becoming faster and simpler with every action we take. Creating the best health care value for our customers Investing where returns are the greatest to make the best use of our current assets. Being a market leader in each of our chosen businesses. Continuing to advocate for responsible health care reform.
Health Republic Insurance of New York is a not-for-profit health insurance CO-OP (Consumer Operated and Oriented Plan) established under the Affordable Care Act to expand affordable healthcare options for all New Yorkers. Our high-quality plans are available to individuals and small groups, both on exchange and off, throughout the state. Since we opened our doors in October of 2013, we`ve enrolled over 145,000 members, making us the largest health insurance cooperative in the country and one of the fastest growing insurance companies in New York history. Our tremendous success is a testament to the way our values resonate with our members.
Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona’s lead program is an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome (MPS IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. Clinical trials for Sanfilippo types A and B are anticipated to begin in 2015.